ArticlePloS one2013
Protective effects of mesenchymal stem cells with CXCR4 up-regulation in a rat renal transplantation model.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization.Cells · 2026Review
- CXCR4 is a response gene for parathyroid hormone which affects osteoblast and osteoclast function in vitro.Bone & joint research · 2025Article
- The Therapeutic Use and Potential of MSCs: Advances in Regenerative Medicine.International journal of molecular sciences · 2025Review
- CXCR4Stem cells international · 2022Article
- Molecular Mechanisms of Mesenchymal Stem Cell-Based Therapy in Acute Kidney Injury.International journal of molecular sciences · 2021Review
- Review
- Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.Stem cells translational medicine · 2021Review
- The Role of CXCL12 in Kidney Diseases: A Friend or Foe?Kidney diseases (Basel, Switzerland) · 2021Review
- When Origin Matters: Properties of Mesenchymal Stromal Cells From Different Sources for Clinical Translation in Kidney Disease.Frontiers in medicine · 2021Review
- Surface tethering of stromal cell-derived factor-1α carriers to stem cells enhances cell homing to ischemic muscle.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Preconditioning is an effective strategy for improving the efficiency of mesenchymal stem cells in kidney transplantation.Stem cell research & therapy · 2020Review
- Improved therapeutics of modified mesenchymal stem cells: an update.Journal of translational medicine · 2020Review
- Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation.Frontiers in immunology · 2020Review
- Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection.Frontiers in cell and developmental biology · 2020Article
- Protective effect of bone marrow mesenchymal stem cells modified with klotho on renal ischemia-reperfusion injury.Renal failure · 2019Article
- Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.Transplantation · 2019Article
- Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy.Scientific reports · 2017Article
- Mesenchymal stromal cells in renal transplantation: opportunities and challenges.Nature reviews. Nephrology · 2016Review
- Genetic Engineering of Mesenchymal Stem Cells to Induce Their Migration and Survival.Stem cells international · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The homing of mesenchymal stem cells to injured tissue, which is important for the correction of conditions such as ischemia-reperfusion injury (IRI) and immunolesions, has been performed previously, but with poor efficiency. Substantial improvements in engraftment are required to derive clinical benefits from MSC transplantation. Chemokines are the most important factors that control cellular migration. Stromal derived factor-1 (SDF-1) is up-regulated during tissue/organ ischemia damage, and its cognate receptor, chemokine receptor 4 (CXCR4), is involved in stem cell migration. The aim of our study was to investigate CXCR4 expression in MSCs and to validate both its role in mediating migration to transplanted kidneys and its immunoregulatory effects in renal protection. Specifically, the present study was designed to investigate the short-term tissue homing of MSCs carrying genetically modified CXCR4 in a rat renal transplantation model. We tested the hypothesis that MSCs with CXCR4 over-expression can more efficiently regulate immunological reactions. Lentiviral vectors were used to over-express CXCR4 or to introduce a short hairpin ribonucleic acid (shRNA) construct targeting endogenous CXCR4 in rat MSCs. MSCs were labeled with enhanced green fluorescent protein (eGFP). After cell sorting, recipient kidneys were regionally perfused; recipient animals were injected with transduced MSCs, native MSCs, or PBS via tail vein following renal transplantation; and the effects of MSC injection were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.